Market Overview

Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO


Calyxt to host conference call on Wednesday, August 22, 2018 at 8:30
a.m. ET – 7:30 a.m. CT

GROWTH: ALCLS) announced today its Board of Directors has appointed Yves
Ribeill, Ph.D., as Interim Chief Executive Officer, effective
immediately. Dr. Ribeill replaces Federico Tripodi, who is leaving the
Company to pursue other opportunities. Currently a member of Calyxt's
Board of Directors, Dr. Ribeill will work closely with the executive
management team to promote the development of the Company's products to
benefit consumers, including the commercial launch of Calyxt's
high-oleic soybean oil.

In addition, the Board of Directors of Calyxt appointed Jonathan
Fassberg, founder of the Trout Group and currently Co-Chief Executive
Officer of Solebury Trout, as a member of the Board of Directors and a
member of the Audit Committee.

"Given Yves' extensive prior experience in healthcare, coupled with his
strategic abilities, business development experience and broad network,
the Board is confident he will bring the right combination of skills
necessary to succeed during this pivotal period for Calyxt," said Dr.
André Choulika, Chairman of Calyxt's Board of Directors. "The Company is
making significant strides to develop healthy food products for
consumers, and we expect Dr. Ribeill to solidify Calyxt's position as a
leader in the field." Dr. Choulika added, "the Company would like to
thank Mr. Tripodi for his service as CEO and wishes him the very best in
his future endeavors".

"Healthy eating and healthy living go hand-in-hand," added Dr. Ribeill.
"I strongly believe that Calyxt will play a vital role in keeping people
healthy across the world, and the Company has enormous potential to
create foods that exhibit healthy characteristics. At Calyxt, we have
the unique opportunity to lead an important trend in agriculture towards
creating healthier crops and food ingredients. We view it as our duty to
address the health and nutrition concerns of today's society by
developing better, more nutritious foods for consumers."

Yves Joseph Ribeill, Ph.D., founded SCYNEXIS, Inc (NASDAQ:SCYX) and
served as President and CEO from 1999 to 2015. Dr. Ribeill has more than
35 years of experience in the healthcare industry, with an expertise in
anti-infective diseases including bacterial, fungal, viral and
parasiticidal and in microbiome-centric diseases. Prior to moving to the
U.S. 21 years ago, Dr. Ribeill held several management positions during
his international career with Rhône-Poulenc and Aventis in France and in
the UK. Dr. Ribeill was a member of the Scientific Advisory Committee of
the World Health Organization, the Medicines for Malaria Venture and is
currently Vice Chairman of the Triangle Global Health Consortium in
North Carolina.

Conference Call Details
Calyxt to hold a conference call for
investors Wednesday, August 22, 2018 at 8:30a.m. ET – 7:30a.m. CT.
live dial-in information for the conference call is:
US & Canada
only: 877-407-9747
International: 412-902-0044

Replay Information
Conference ID #: 13673206
Dial-In (Toll Free US & Canada): 877-660-6853
Replay Dial-In
(International): 201-612-7415
Expiration Date: 9/5/18

Webcast URL (archived for 6 months):

About Calyxt
Calyxt, Inc. is a consumer-centric, food- and
agriculture-focused company. Calyxt is pioneering a paradigm shift to
deliver healthier food ingredients, such as healthier oils and high
fiber wheat, for consumers and crop traits that benefit the environment
and reduce pesticide applications, such as disease tolerance, for
farmers. Calyxt develops non-transgenic crops leveraging processes that
occur in nature by combining its leading gene-editing technology and
technical expertise with its innovative commercial strategy. Calyxt is
located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market

For further information please visit our website:
and the corporate logo are trademarks owned by Calyxt, Inc.

TALEN® is a registered trademark owned by the Cellectis S.A.

Forward-Looking Statements
This communication contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
In some cases, you can identify these statements by forward-looking
words such as "may," "might," "will," "should," "expects," "plans,"
"anticipates," "believes," "estimates," "predicts," "potential" or
"continue," the negative of these terms and other comparable
terminology. These forward-looking statements, which are subject to
risks, uncertainties and assumptions about us, may include projections
of our future financial performance, our anticipated growth strategies
and anticipated trends in our business. These statements are only
predictions based on our current expectations and projections about
future events. There are important factors that could cause our actual
results, level of activity, performance or achievements to differ
materially from the results, level of activity, performance or
achievements expressed or implied by the forward-looking statements,
including those factors discussed under the caption entitled "Risk
Factors" in Calyxt's Annual Report on Form 10-K, and Cellectis' Annual
Report on Form 20-F and the financial report (including the management
report) for the year ended December 31, 2017 along with other Calyxt and
Cellectis subsequent filings with the U.S. Securities and Exchange
Commission. We do not assume any obligation to publicly provide
revisions or updates to any forward-looking statements, whether as a
result of new information, future developments or otherwise, should
circumstances change, except as otherwise required by applicable laws.

View Comments and Join the Discussion!